Targeted cancer treatments: ROS1+
Molecular diagnosis highlights the “weak spots” in each oncology patient and allows the administration of a treatment that specifically targets these weak spots, resulting in a more effective treatment with fewer side effects.
One of these weaknesses is the ROS1 gene. When it becomes abnormal, it can promote the growth and survival of certain tumours.
Up to 1-2% of non-small cell lung cancers (NSCLC) are ROS1+, but this alteration has also been found in other solid tumours (cholangiocarcinoma, pancreas, glioblastoma, liver, etc.).
There are currently drugs, belonging to the group of tyrosine kinase inhibitors (TKIs), which target ROS1-positive cancer. These oral drugs act to inhibit this abnormal activity, consequently delaying the development of the tumour, being more effective and with fewer side effects than chemotherapy for many patients.
Unfortunately, TKIs are not a definitive treatment; over time tumours acquire resistance mechanisms and the drug no longer works, but research is progressing and new treatment strategies are being developed against specific ROS1 alterations and their resistance mechanisms. Currently there are several active clinical trials in our country with very promising initial results.
Don’t hesitate to consult our experts for further information on ROS1.
Other resources you can access are the website of the Spanish Association of Lung Cancer Patients or the website of the international patient group.
